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A 19-year-old boy with a 7-year
history of extensive ulcerative colitis
(UC), in remission for 4 years with
azathioprine 2.5 mg/kg/d, was admitted
reporting a 3-day history of fever (39–
40C), headache, and abdominal dis-
comfort. He denied other symptoms.
Physical examination showed fever
(40C), jaundice, generalized lympha-
denopathies (cervical, submandibular,
occipital, pre-auricular, axillary, and
inguinal, up to 3 cm in diameter),
painless hepatosplenomegaly, and
peripheral edema. Laboratory data on
admission revealed pancytopenia
(hemoglobin 8.1 g/dL, leukocytes 0.6
 103 U/L, platelets 45  103 lL)
decreased prothrombinemia (37%),
hypoﬁbrinogenemia (1.4 g/L), hypoal-
buminemia (2.8 g/dL), positive C-reac-
tive protein (12.4 mg/dL), increased
ferritin (10,080 ng/dL), and liver
enzymes (AST 342 U/L, ALT 165 U/
L, AF 802 U/L, GGT 715 U/L, biliru-
bin 21 U/L), increased triglyceride val-
ues (633 mg/dL), decreased NK cells
(<1%), and increased proteins in urine
(3237 mg).
Thoracoabdominal computed to-
mography (CT) showed small bilateral
pleural effusion, multiple and bilateral
lymphadenopathies, homogenous hepa-
tomegaly, splenomegaly with pericen-
trimetic hypodense nodular lesions,
and peri-hepatic, peri-splenic ascitic
ﬂuid. Several blood, urine, sputum,
and stool cultures were negative.
Tuberculin skin test was nonreactive.
Serum immunoglobulin G and M anti-
bodies against Epstein–Barr virus
(EBV) viral capsid antigen were pres-
ent, but EBNA was negative. It
became positive in 11 days. Serologies
for other common viruses were nega-
tive, as well as autoantibodies. At this
point infectious mononucleosis alone
did not seem to explain this exuberant
clinical picture. Therefore, a lympho-
proliferative disorder was investigated.
Bone marrow aspirate revealed an
increased number of histiocytes with
hemophagocytosis (Fig. 1). Histopatho-
logic study of a cervical lymph node
showed expansion of T area with
EBV-positive cells.
A diagnosis of hemophagocytic
lymphohistiocytosis secondary to
recent EBV infection was established.
He was ﬁrst treated with prednisolone
(maximum dose 2 mg/kg) and 8 days
later, intravenous immunoglobulin (0.5
g/day for 3 consecutive days) with
clinical improvement. Broad-spectrum
antibiotics, blood transfusions of eryth-
rocytes and platelets, ﬁbrinogen, and
granulocyte-colony-stimulating factor
were also used.
The patient was discharged at
day 33 after admission. One year later




properly referred to as hemophagocytic
lymphohistiocytosis (HLH), is a clini-
cal pathological entity characterized by
fever, pancytopenia, splenomegaly, and
the pathological ﬁnding of hemophago-
cytosis in bone marrow and other tis-
sues.1 First described by Scott and
Robb-Smith in 1939, is characterized
by a deﬁciency in cytolytic activity
(impaired or absent function of NK
cells and cytotoxic T cells), resulting
in persistent activation of lymphocytes
and histiocytes. This uncontrolled and
inappropriate immune response leads
to hypersecretion of proinﬂammatory
cytokines and uncontrolled hemopha-
gocytosis throughout the reticuloendo-
thelial system.2
Diagnosis of HLH relies on spe-
ciﬁc clinical, laboratory, and histopath-
ological ﬁndings, proposed by the His-
tiocyte Society in 1991 and updated in
2004.3 The diagnosis can be established
if ﬁve of the eight criteria are fulﬁlled,
namely, clinical criteria (fever for more
than 7 days and splenomegaly), labora-
tory criteria (bicytopenia without mar-
row hypoplasia, hypertriglyceridemia,
and/or hypoﬁbrinemia, hyperferritine-
mia, low/absent NK cell activity,
increased soluble CD25 levels), and his-
tological criteria (hemophagocytosis
which can be seen in any organ, but is
particularly common in bone marrow,
lymph nodes, liver, and spleen). Jaun-
dice, hepatomegaly, lymphadenopathy,
rash, and neurological signs are also
common. Common laboratory ﬁndings
are high bilirubin levels, elevated serum
transaminases, elevated prothrombin,
and partial thromboplastin times.4
The main diagnostic problem is
that initially HLH masquerades as a
normal infection and too little attention
is paid to the severity of symptoms.
When a patient presents with pro-
longed fever unresponsive to antibiot-
ics, hepatosplenomegaly, and cytope-
nias, HLH as a differential diagnosis
should be considered. Unfortunately,
hemophagocytosis is often absent ini-
tially, but can be more easily detected
as the syndrome progresses. The ab-
sence of hemophagocytosis is often the
reason why the diagnosis of HLH is
ruled out as unwarranted. Therefore, if
hemophagocytosis is absent in initial
biopsy specimens, the biopsy may be
need to be repeated in cases with high
suspicion.5
This clinical syndrome occurs in
all age groups and may be encountered
with a variety of underlying conditions,
namely, genetic (autosomal or x-linked)
or acquired (more commonly associated
with viral infections, although bacterial
and parasites may be involved; malig-
nancies and autoimmune diseases).
This distinction is not categorical, as
primary HLH can occur late in life and
may be triggered by infections.4
Without treatment, the uncon-
trolled hyperinﬂammation leads to
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sustained neutropenia with opportunistic
infections or even to cerebral dysfunc-
tion. It is a life-threatening condition
which may be difﬁcult to distinguish
from severe sepsis. Poor prognosis
appears to be determined by the pres-
ence of disseminated intravascular coag-
ulation, coexisting signiﬁcant hepatic,
renal or respiratory dysfunction, and sus-
tained hyperferritinemia.6
The overall mortality rate ranges
across studies from 22%–59%. HLH
related to hematological malignancies
or EBV infection carries a higher mor-
tality rate than cases related to viruses
or intracellular bacteria.1,7,8
Treatment is based on control of
the cytokine storm and cellular prolifer-
ation. Immunochemotherapy as pro-
posed by the Study Group of the His-
tiocyte Society (ﬁrst international
protocol in 1994, updated in 2004) con-
sists of combination therapy with etopo-
side, dexamethasone, and cyclosporine
A, as well as, in selected patients with
central nervous system involvement, in-
trathecal therapy with methotrexate and
corticosteroids.3 Subsequent hematopoi-
etic stem cell transplantation is recom-
mended for patients with familial dis-
ease or molecular diagnosis, and
patients with severe and persistent, or
reactivated, disease. In order to further
improve diagnosis, therapy, and biologi-
cal understanding, participation in HLH
studies is encouraged.7 The administra-
tion of IvIG has also been established.6
EBV-speciﬁc therapy in treating
EBV-associated hemophagocytic syn-
drome remains uncertain, although
larger trials are needed to assess the
effectiveness of speciﬁc anti-EBV ther-
apy in EBV-associated HLH.9 Antivi-
ral therapy with acyclovir, ganciclovir,
or cidofovir are generally ineffective
in EBV-HLH. Acyclovir and ganciclo-
vir (alone, with IvIG or steroids plus
IvIG) have achieved a reduction in
EBV DNA levels and clinical
improvement in isolated case reports.6
In HLH 2004, it is recommended that
antiviral agents are considered when
ongoing viral infection is apparent.3
As highlights, we emphasize an
unusual successful HLH secondary to
viral infection in an immunosuppressed
19-year-old boy. This diagnosis should
always be considered in young patients
with marked bone marrow dysfunction
and multiple organ failure. Management
of this syndrome relies on early diagno-
sis, identiﬁcation of a triggering patho-
gen or an underlying disease, and con-
trol of the lymphocyte/macrophage
proliferation and activation. The wide-
spread use of immunosuppressive ther-
apy in the treatment of inﬂammatory
bowel disease (IBD) places patients at
risk of infection and so at risk of HLH.
Patients who present with fever and
cytopenia should be evaluated for HLH.
Gabriela Duque, MD*
Rosa Ferreira, MD*
Pedro Figueiredo, MD, PhD*
Isabel Sousa, MD†
Manuela Ferreira, MD*




Jose´ Manuel Roma˜ozinho, MD, PhD*
Carlos Soﬁa, MD, PhD*
*Gastroenterology Department
Coimbra University Hospital, Coimbra
Portugal
†Hematology Department
Coimbra University Hospital, Coimbra
Portugal
REFERENCES
1. Cre´put C, Galicier L, Buyse S, et al. Under-
standing organ dysfunction in hemophagocytic
lymphohistiocytosis. Intensive Care Med.
2008;34:1177–1187.
2. Rouphael NG, Talati NJ, Cunningham K,
et al. Infections associated with haemophago-
cytic syndrome. Lancet Infect Dis. 2007;7:
814–822.
3. Henter JI, Horne A, Arico´ M, et al. HLH-
2004: Diagnostic and therapeutic guidelines
for hemophagocytic lymphohistiocytosis.
Pediatr Blood Cancer. 2007;48:124–131.
4. Maakaroun N, Moanna A, Jacob J, et al. Viral
infections associated with haemophagocytic
syndrome. Rev Med Virol. 2010;20:93–105.
5. Gritta E. Hemophagocytic syndromes. Blood
Rev. 2007;21:245–253.
6. Barry PA, Bernal W, Pagliuca A, et al. Multi-
ple organ failure and severe bone marrow
dysfunction in two 18 years-old Caucasian
patients: Epstein-Barr virus and the haemo-
phagocytic syndrome. Anaesthesia. 2008;63:
1249–1254.
7. Imashuku S, Teramura T, Tauchi H, et al.




8. Imashuku S, Kuriyama K, Terramura T, et al.
Requirement for ectoposide in the treatment
of Epstein-Barr virus associated hemophago-
cytic lymphohistiocytosis. J Clin Oncol. 2001;
19:284–287.
9. James DG, Stone CD, Wang HL, et al. Reac-
tive hemophagocytic syndrome complicating
the treatment of inﬂammatory bowel disease.
Inﬂamm Bowel Dis. 2006;12:573–580.
FIGURE 1. Hemophagocytosis in bone marrow aspirate. [Color ﬁgure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
Inﬂamm Bowel Dis  Volume 17, Number 6, June 2011 Letters to the Editor
E65
